BOSTON--(BUSINESS WIRE)--Strand Therapeutics, the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient ...

Messenger RNA brought the world its first Covid-19 vaccines, demonstrating along the way how this technology works. Strand Therapeutics is developing what could become the next generation of mRNA ...

For many, mRNA-based medicines are synonymous with COVID-19 vaccines, but vaccination is just the tip of the iceberg for the technology. Strand Therapeutics is one of the companies looking below the ...

An impressive array of Big Pharma backers lined up to ensure Strand Therapeutics has the funding needed to take its mRNA-based solid tumor drug further into the clinic. New Strand supporters that ...

As a grad student in biological engineering at MIT, Jake Becraft had an idea that could change the way we treat cancer: What if genes could be turned on and off like light switches? Thinking it ...

-- Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 ...

Close to getting his PhD, Jake Becraft was wondering what he should do with his career–and then a friend called with a PowerPoint. Becraft was at the Massachusetts Institute of Technology, completing ...

How does DNA determine an organism’s characteristics? A process called translation decodes RNA created during transcription, and uses it to create proteins that perform specific cellular functions.

Strand Therapeutics has added to its series A funding from last year, bringing the total to $97 million. The messenger RNA (mRNA) therapeutics company is gearing up to bring its lead drug candidate, ...

Members of the Strand Therapeutics team: Samta Kundu, chief operating officer; Jake Becraft, CEO, cofounder; Tasuku Kitada, president, head of R&D, cofounder. The Covid-19 pandemic introduced millions ...